Prophylactic implantable cardiac defibrillators require a baseline risk for arrhythmic death of ≥3% per year to achieve a clinically meaningful number needed to treat of 50 to prevent one death.
Cohort
Yes
What is the baseline risk of arrhythmic death required for prophylactic ICDs to provide clinically meaningful survival benefits in patients with LV dysfunction?
Prophylactic ICDs require a baseline risk of arrhythmic death of at least 3% per year to achieve a clinically meaningful number needed to treat of 50 for preventing one death.
OBJECTIVE: To estimate the baseline risk of arrhythmic death required for prophylactic implantable cardiac defibrillators (ICDs) to result in clinically meaningful survival benefits in the population. BACKGROUND: While proven efficacious, the absolute survival impact of ICDs for the primary prevention of sudden cardiac death among patients with left ventricular (LV) dysfunction is highly dependent upon patient's baseline risk of arrhythmic death. METHODS: Using echocardiographic data from a random sample of patients identified from community echocardiographic laboratories, patients with moderate or severe LV dysfunction (ejection fraction < 35%) were linked to administrative databases to characterize baseline mortality risk (median follow-up duration of 4.85 years). Relative efficacy was ascertained from meta-analysis and clinical trial data. The baseline annual risk of arrhythmic death required for prophylactic ICDs to result in clinically meaningful survival benefits in the population was estimated at different ranges of relative efficacy and numbers needed to treat (NNTs) thresholds. RESULTS: LV dysfunction was a significant independent predictor of adverse outcomes. In total, 35.4% of the patients with moderate to severe LV dysfunction died during the follow-up period. Assuming a base-case relative efficacy of 66%, we estimated that the baseline risk for arrhythmic death required to exert a clinically meaningful NNT threshold of 50 in order to prevent one death (from any cause) was 3% per year or higher. CONCLUSIONS: The survival impact and cost-effectiveness of prophylactic ICDs in the population will depend upon the ability to risk-stratify and identify patients whose baseline risk for sudden cardiac death exceed 3% per year.
Jolly et al. (Tue,) conducted a cohort in Moderate or severe left ventricular dysfunction (ejection fraction < 35%). Prophylactic implantable cardiac defibrillators (ICDs) was evaluated on Baseline risk for arrhythmic death required to exert a clinically meaningful NNT threshold of 50 to prevent one death. Prophylactic implantable cardiac defibrillators require a baseline risk for arrhythmic death of ≥3% per year to achieve a clinically meaningful number needed to treat of 50 to prevent one death.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: